This study aimed to assess the role of Dienogest pretreatment for endometriosis suppression as compared to Gonadotropin-releasing hormone agonist (GnRHa) in patients with endometriosis pursuing IVF treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
134
Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF
Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)
Minia Infertility research unit
Minya, Egypt
the number of retrieved oocytes
the number of retrieved oocytes as the main concern was the effect of either GnRHa or Dienogest on ovarian responsiveness
Time frame: After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest)
the fertilization rate
defined as the number of zygotes with two pronuclei divided by the number of oocytes
Time frame: After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest)
the number of transferrable embryos
defined as the number of embryos suitable for transfer in the stimulated cycle or cryopreservation
Time frame: After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest)
the cost of the treatment
the cost of the treatment in Egyptian pounds including cost of pretreatment and ovarian stimulation drugs
Time frame: After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest)
pregnancy rate per cycle started
defined as patients with positive urinary or serum pregnancy test divided by the number of patients starting the treatment
Time frame: After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest)
the clinical pregnancy rate per cycle started
defined as the number of patients with at least one intrauterine gestational sac with identifiable fetal heart pulsations over the total number of patients starting the treatment
Time frame: after women have postive pregnancy test (2 weeks after after the embryo transfer)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
the miscarriage rate
defined as patients with identified intrauterine gestational sac without a fetal pole, or a fetal pole with no heart pulsations with no other viable fetuses over the number of patients with positive pregnancy test
Time frame: After occurence of the clinical pregnancy (5 months after after the embryo transfer)
patient's quality of life
patient's quality of life during the pretreatment period as assessed by the Fertility quality of life (FertiQoL) questionnaire with a range of 0 (the worst) to 100 (the best).
Time frame: throughout the pre-treatment with GnRHa or Dienogest as well as the induction of ovulation "through study completion, an average of 9 months"